MapLight Therapeutics' shares dropped more than 50% after its Phase 2 trial for a schizophrenia drug showed mixed results, failing to meet the primary endpoint with statistical significance. This sharp decline led Schall, Brown & Schwartz LLP to investigate potential securities law violations, including whether MapLight misled investors or withheld important information. Investors who suffered losses are encouraged to contact the law firm for possible legal action. This case highlights risks in biotech investments tied to clinical trial outcomes.
WeRide, a global leader in autonomous driving technology, and GreenMobility, a leading Danish electric shared mobility provider, announced a strategic partnership to introduce Level 4 autonomous shared mobility services in Denmark. This marks WeRide'...
FLSmidth & Co. A/S continued its share buy-back programme initiated in May 2026, repurchasing 64,000 shares between July 27 and July 31, 2026, at an average price ranging from DKK 470.35 to DKK 487.27 per share. This brings the total shares bought ba...
Danone and Arcor have completed the creation of a joint venture in Argentina, combining Danone's dairy operations with Arcor's Mastellone Hermanos and their shared logistics subsidiary. This partnership leverages over 20 years of collaboration to enh...
ArcelorMittal is expanding its collaboration with Microsoft to accelerate its digital transformation by adopting Microsoft Azure as its primary cloud platform. This move supports ArcelorMittal's 'Cloud First, Data Centric' strategy, enabling the comp...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of the latest transactions in late July 2026, the bank has repurchased 1,642,524 shares at an average price of DKK ...
